Rigel Pharmaceuticals, Inc. (RIGL)
39.65
-6.06
(-13.26%)
USD |
NASDAQ |
Nov 06, 16:00
39.60
-0.05
(-0.13%)
After-Hours: 20:00
Rigel Pharmaceuticals Enterprise Value : 684.25M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 684.25M |
| November 05, 2026 | 797.29M |
| November 04, 2026 | 901.38M |
| November 03, 2026 | 856.05M |
| November 02, 2026 | 887.20M |
| October 30, 2026 | 901.75M |
| October 29, 2026 | 904.36M |
| October 28, 2026 | 891.12M |
| October 27, 2026 | 887.58M |
| October 26, 2026 | 875.64M |
| October 23, 2026 | 842.43M |
| October 22, 2026 | 856.05M |
| October 21, 2026 | 856.42M |
| October 20, 2026 | 842.06M |
| October 19, 2026 | 816.13M |
| October 16, 2026 | 802.14M |
| October 15, 2026 | 826.02M |
| October 14, 2026 | 818.00M |
| October 13, 2026 | 823.97M |
| October 12, 2026 | 855.12M |
| October 09, 2026 | 860.15M |
| October 08, 2026 | 853.44M |
| October 07, 2026 | 839.82M |
| October 06, 2026 | 804.75M |
| October 05, 2026 | 836.09M |
| Date | Value |
|---|---|
| October 02, 2026 | 824.15M |
| October 01, 2026 | 820.79M |
| September 30, 2026 | 842.81M |
| September 29, 2026 | 856.61M |
| September 28, 2026 | 865.38M |
| September 25, 2026 | 843.37M |
| September 24, 2026 | 837.96M |
| September 23, 2026 | 842.43M |
| September 22, 2026 | 855.30M |
| September 21, 2026 | 823.03M |
| September 18, 2026 | 814.64M |
| September 17, 2026 | 799.90M |
| September 16, 2026 | 774.35M |
| September 15, 2026 | 772.11M |
| September 14, 2026 | 790.58M |
| September 11, 2026 | 825.83M |
| September 10, 2026 | 826.58M |
| September 09, 2026 | 825.46M |
| September 08, 2026 | 828.26M |
| September 04, 2026 | 852.51M |
| September 03, 2026 | 849.34M |
| September 02, 2026 | 866.50M |
| September 01, 2026 | 830.68M |
| August 31, 2026 | 806.06M |
| August 28, 2026 | 811.65M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cytokinetics, Inc. | 7.614B |
| Inovio Pharmaceuticals, Inc. | 71.37M |
| United Therapeutics Corp. | 21.75B |
| Verastem, Inc. | 708.93M |
| Marker Therapeutics, Inc. | 2.963M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 17.29M |
| Revenue (Quarterly) | 78.70M |
| Total Expenses (Quarterly) | 61.41M |
| EPS Diluted (Quarterly) | 0.8835 |
| Gross Profit Margin (Quarterly) | 89.17% |
| Profit Margin (Quarterly) | 21.97% |
| Earnings Yield | 41.17% |
| Operating Earnings Yield | 11.23% |
| Normalized Earnings Yield | 41.18 |